Monaco

Key Insights

1
No psychedelic therapy is publicly approved in Monaco; patients mainly access standard psychiatry, while ketamine would be confined to general medical use and prescribing rules.
2
Monaco shows just 1 registered trial, 0 active studies, and 1 research organisation; ketamine and placebo are the only tracked compounds.
3
Monaco’s modern research profile is tiny, but its healthcare system is universal for citizens and long-term residents, supporting rare specialist studies.
4
Momentum is fragile: with no active psychedelic trials, the field depends on one institution and any future protocol, funding round, or regulatory opening.

Medical Only (Private)

Reimbursed Care Access

Monaco maintains a restrictive controlled‑substances regime: classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are treated as illicit with no routine medical programs outside approved research. Esketamine (Spravato) is authorised at the European level and therefore may be prescribed/obtained within Monaco subject to national/ministerial marketing and reimbursement decisions; racemic ketamine is used off‑label in psychiatric practice in Europe but access is typically private and not routinely reimbursed without specific ministerial listing or exceptional procedures.

Full guide →